Navigation Links
Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia

an Hgb level was 10.2 g/dL at study entry and was increased to greater than 11 g/dL following an initial dose of Hematide. In the maintenance-conversion study, 90 patients previously treated with Epoetin alfa were switched to Hematide once every four weeks. The mean baseline Hgb level, which was 11.5 g/dL at baseline, was maintained within +/- 1.0 g/dL at the end of six months of treatment. Hematide was generally well tolerated and compatible with adverse events usually observed in patients with chronic kidney disease, with 6 percent of patients reporting adverse events possibly related to Hematide such as fatigue, rash and hypertension and 0.7 percent of patients reporting serious adverse events possibly related to Hematide (one transient ischemic attack in a patient with history of atrial fibrillation, and one moderate infusion reaction in a patient who responded to outpatient intervention).

About Hematide

Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in patients with chronic renal failure and cancer patients receiving chemotherapy.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic renal failure and cancer. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding the timing, design and results of the Company's clinical trials and drug development program, the timing and likelihood of the commercialization of Hematide. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
2. Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

Post Your Comments:
(Date:11/9/2009)... TOWN OF HEMPSTEAD, N.Y., Nov. 9 /PRNewswire/ -- ...ice officers and other rescue workers came togethe...ty. Merrick firefighter Brian McCauley was one of ... save his own life. ,, Only in his late 30s, Mc...ndergone surgery and extensive chemotherapy treatm...
(Date:11/9/2009)... PALO ALTO, Calif., Nov. 9 Women,s...t has changed its name to Viveve as it prepares fo... select U.S. markets. ,, "Viveve is a name that...cus on women,s sexual health," said Kerry Pope, Vi...ts for the sole purpose of helping women restore t...
(Date:11/9/2009)... NATICK, Mass., Nov. 9 B...nnounced the launch of its COGNIS® cardiac re...TELIGEN® implantable cardioverter defibrillat... the Japanese Ministry of Health, Labor and Welfar...oval in September. COGNIS and TELIGEN are the res...
Breaking Medicine Technology:The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3Women's Sexual Health Company Changes Name in Preparation for Market Entry 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 3Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 4Microbes and their hosts exploring the complexity of symbiosis in DNA and cell biology 9396 1Microbes and their hosts exploring the complexity of symbiosis in DNA and cell biology 9396 2Study shows cancer vaccines led to long term survival for patients with metastatic melanoma 9391 1Study shows cancer vaccines led to long term survival for patients with metastatic melanoma 9391 2Valve Repair First in New England Done With Robotic Device 52959 1Valve Repair First in New England Done With Robotic Device 52959 2Valve Repair First in New England Done With Robotic Device 52959 3
...05, 2007 /PRNewswire/ -- Results from,the primary ...Phase,3 study showed that 77 percent of treatment-...TM) (darunavir) 600 mg tablets with,100 mg ritonav...kground regimen (OBR) of antiretroviral (ARV) agen...at week 48, compared to 68,percent of patients tak...
...INESS WIRE)--Jul 9, 2007 - ZIOPHARM,Oncology, Inc....ta,from an ongoing phase II trial of ZIO-201 (isop...oma patients was presented at the,European Society...,2007 in Lugano, Switzerland. The abstract entitle...Sarcoma," was presented by,Rashmi Chugh, MD, a Pri...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:11/9/2009)...Study didn,t answer question of why this is so, ho...ws) -- After a lumpectomy, women with very dense b...the affected breast, a new study shows. , Breas...d risk of developing breast cancer, and experts ha...ssociated with an increased risk of cancer recurre...
(Date:11/9/2009)...,, CAMBRIDGE, Mass., Nov. 9 A...nd capabilities in delivering emergency management...ly awarded contracts to support the work of the Fe...of Regional Operations, the National Commission on...litan Area Transit Authority (WMATA). The value o...
(Date:11/9/2009)...,, WASHINGTON, Nov. 9 /PRNewswire-USNewswire/ -...PA), representing more than 75,000 clinically prac...e United States, applauds the U.S. House of Repres...orm bill, H.R. 3962, the Affordable Health Care fo...that this reform bill will ultimately lower the co...
(Date:11/9/2009)... This release is available in French . , ,... came in twos: male and female. In human bodies tr...molecules from which they are composed. Yet these...tinguishable clusters. Because these complex cell ...ientists have long searched for ways to splice cel...
(Date:11/9/2009)... As many as 10 million people around the world su...niversity in Frankfurt and his coauthors discuss c...cial lens in the current issue of Deutsches rzteb...[43]: 695�). , Blindness is usually due t...e than 600,000 cataract operations are performed e...
Breaking Medicine News(10 mins):Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 2Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2
... with high infection rates has got support from Bi... a stigma attached to the deadly illness and the l...o and so AIDS testing was frowned upon. Accord...er universal testing. As told to journalists ...
...al of a new technology called nanotechnology, it o... more than an eccentric concept //. The term ‘Nano...y small machines from nanometer size units that ar...rnment organizations and multinational companies a...
...ple and natural remedy for reducing the intensity .../ by just eating more fruits and vegetables. They ...in antioxidants, are capable of accelerating and w...s of antioxidants, like carotene and lycopene in t...
...erta confirms the popular myth that Rodeo cowboys ...n whiplash injuries, Dr. Robert Ferrari, clinical ...y of Alberta, has found that conducted the cultura...th Faculty of Agriculture of the University of Alb...
...nducted this study which was self funded. The swee... or sourness of the sweetener. // The researchers ...ked to rate 13 different sweeteners and sweet subs...und sucralose (brand name Splenda), a sweetener de...
... confirmed coliform bacteria and diatoms in some s...Spring Water//, Ltd. For this reason North Countr...ecalling all of its bottled water products. Colif...nitary Code. Coliform bacteria may indicate the pr...
Other Medicine News:Health News:Nanotechnology Promises Huge Medical Benefits 2Health News:Quick Recovery in Rodeo Athletes 2Health News:Sweet, Sweeter and Sweetest 2
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: